ALK and non-small cell lung carcinoma: The approval of the Abbott Vysis break-apart FISH assay by the FDA as the CDx for the diagnosis of ALK-rearranged NSCLC seemed to have established break-apart FISH as the lead method platform to diagnose RTK rearrangement in NSCLC.